scholarly journals Use of Mycobacterium tuberculosisComplex-Specific Antigen Cocktails for a Skin Test Specific for Tuberculosis

1998 ◽  
Vol 66 (8) ◽  
pp. 3606-3610 ◽  
Author(s):  
Konstantin Lyashchenko ◽  
Claudia Manca ◽  
Roberto Colangeli ◽  
Anna Heijbel ◽  
Alan Williams ◽  
...  

ABSTRACT The tuberculin skin test currently used to diagnose infection withMycobacterium tuberculosis has poor diagnostic value, especially in geographic areas where the prevalence of tuberculosis is low or where the environmental burden of saprophytic, nontuberculous mycobacteria is high. Inaccuracy of the tuberculin skin test often reflects a low diagnostic specificity due to the presence in tuberculin of antigens shared by many mycobacterial species. Thus, a skin test specific for tuberculosis requires the development of new tuberculins consisting of antigens specific to M. tuberculosis. We have formulated cocktails of two to eight antigens of M. tuberculosis purified from recombinant Escherichia coli. Multiantigen cocktails were evaluated by skin testing guinea pigs sensitized with M. bovis BCG. Reactivity of multiantigen cocktails was greater than that of any single antigen. Cocktail activity increased with the number of antigens in the cocktail even when the same amount of total protein was used for cocktails and for each single antigen. A cocktail of four purified antigens specific for the M. tuberculosis complex elicited skin test responses only in BCG-immunized guinea pigs, not in control animals immunized with M. avium. These findings open the way to designing a multiantigen formulation for a skin test specific for tuberculosis.

2000 ◽  
Vol 68 (2) ◽  
pp. 990-993 ◽  
Author(s):  
Roberto Colangeli ◽  
John S. Spencer ◽  
Pablo Bifani ◽  
Alan Williams ◽  
Konstantin Lyashchenko ◽  
...  

ABSTRACT In a search for new skin test reagents specific for tuberculosis, we found that the antigen encoded by gene Rv3874 of Mycobacterium tuberculosis elicited delayed-type hypersensitivity in M. tuberculosis-infected guinea pigs but not in control animals immunized with Mycobacterium bovis bacillus Calmette-Guérin (BCG) or Mycobacterium avium. The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.


2004 ◽  
Vol 28 (1) ◽  
pp. 43-54
Author(s):  
G. M. Al - Khatib ◽  
Zainab A.A. Al - Haddad ◽  
Sanaria Fawzi Al- Hissen ◽  
Sahar Hassan Al- Kutbi

 This study was conducted to produce a specific antigen for detection L. monocytogenes infection. The antigen was prepared by culturing L. monocytogenes on suitable media and then disrupted by ultrasonicatorwaves.  The water – soluble extract of sonically disrupted Listeria were used for skin testing guinea pigs infected with (1*108 CFU / ml) of a L. monocytogenes. Two infected doses were used for immunization at intervals of (10) days between them.  Two skin tests were done, 10 days and 15 days after the 2nd infected dose. The skin test results were read after 24 & 48 hrs. which showed clear thickening differences and redness at the injection sites after 24 hrs. and become more clear after 48 hrs.


1997 ◽  
Vol 13 (6) ◽  
pp. 248-251
Author(s):  
Jennifer H Tran ◽  
John D Seeger

Objective: To review the literature discussing the use of two-step tuberculin skin testing for hospital employees. Data Sources: English-language journal articles involving human subjects. Study Selection: Selected articles describing the use of two-step tuberculin skin testing. Data Extraction: Information relevant to the topic was extracted from the articles and synthesized into this report. Data Synthesis: People infected with tuberculosis exhibit a skin-test reaction to tuberculin, but this reaction can diminish over time. A two-step tuberculin skin test involves the administration of a second injection of tuberculin 1–3 weeks after the initial injection. The rationale for the use of the two-step tuberculin skin test is to help differentiate between individuals with new tuberculosis infections and those with previous infections whose immune response to tuberculin had decreased to levels not detectable with a single skin test. Conclusions: Two-step tuberculin skin testing is effective at detecting a booster effect. Despite the recent mandate by the Occupational Safety and Health Administration to use two-step tuberculin testing in all healthcare facilities, such testing may not be cost-effective in institutions with young employees, high employee turnover, and a low risk of tuberculosis. The requirements for universal two-step tuberculin testing may need to be reevaluated to account for these factors.


2007 ◽  
Vol 14 (4) ◽  
pp. 477-480 ◽  
Author(s):  
Willeke P. J. Franken ◽  
Joost F. Timmermans ◽  
Corine Prins ◽  
Evert-Jan H. J. Slootman ◽  
Johan Dreverman ◽  
...  

ABSTRACT The tuberculin skin test (TST) was compared with QuantiFERON-TB Gold in-tube (QFT-GIT) test for the diagnosis of tuberculosis in non-Mycobacterium bovis BCG-vaccinated military personnel. Among subjects positive by TST, 44.4% of recruits were positive by QFT-GIT compared with 11.5% subjects tested after missions abroad, suggesting that most TST conversions in the latter group were caused by nontuberculous mycobacteria.


1950 ◽  
Vol 75 (2) ◽  
pp. 423-426 ◽  
Author(s):  
V. J. Derbes ◽  
J. H. Dent ◽  
N. K. Weaver ◽  
D. D. Vaughan

1977 ◽  
Vol 78 (3) ◽  
pp. 331-348 ◽  
Author(s):  
M. J. Shield ◽  
J. L. Stanford ◽  
R. C. Paul ◽  
J. W. Carswell

SUMMARYFour hundred and seventy tuberculosis patients were each skin tested with four of a range of 17 mycobacterial reagents in four countries in all of which tuberculosis and leprosy were endemic. Sixteen of the reagents were new tuberculins prepared from extracts of living mycobacteria disrupted by ultrasonic disintegration and the last was PPD, RT23.The effect that tuberculosis exerted on the delayed-type skin test response to these antigens was assessed by comparing results for tuberculosis patients with those for Tuberculin positive and Tuberculin negative control populations. Tuberculosis patients on Rifampicin therapy showed no difference in their skin test responses to any of the antigens from those patients on other forms of anti-tuberculosis treatment.Amongst the normal population it was found that possession of Tuberculin positivity was associated with an enhanced response to all the other mycobacterial antigens with the exception of A*-in which demonstrated a reciprocal relationship with Tuberculin in Burma. It was also noted, in Burma particularly, that sensitization to mycobacterial species other than Mycobacterium tuberculosis, especially to the slow growers, plays a role in determining responses to different mycobacterial species.In tuberculosis patients enhanced skin test responses were also seen but only in those countries, e.g. Libya, where the prevalence of mycobacterial species was low. Where mycobacteria were common, as in Burma, the converse was true and tuberculosis was associated with a diminished skin test response to each antigen. The high prevalence of A*-in positivity in Burma, its reciprocal relationship with Tuberculin there and the results for all the antigens in the tuberculosis patients indicate that the cell mediated skin test response may have a threshold. If this is exceeded the skin test becomes negative so that non-reactors then include those who have been excessively sensitized as well as those who have not been sensitized. Despite this, a greater percentage of tuberculosis patients in each country responded to the specific reagent Tuberculin than did the control populations and their mean positive induration sizes were consistently larger. Nevertheless, amongst the tuberculosis patients in Burma 13% were complete non-reactors to Tuberculim and this apparent anergy also applied to the other reagents with which these individuals were tested.This differs from lepromatous leprosy where the anergic state pertain exclusively to M. leprae and a few seemingly closely related species. The breadth of anergy in M. ulcerans infection has not been measured but it is known to effect both Burulin and the PPD, RT23.Just as in leprosy and M. ulcerans infection, tuberculosis can be shown to have a disease spectrum here detected by multiple skin testing. The significance of this spectrum and its similarities with and differences from that of the other mycobacterioses is discussed.


2000 ◽  
Vol 68 (12) ◽  
pp. 7094-7099 ◽  
Author(s):  
Mark A. Chambers ◽  
Ann Williams ◽  
Dolores Gavier-Widén ◽  
Adam Whelan ◽  
Graham Hall ◽  
...  

ABSTRACT Tuberculosis remains one of the most significant diseases of humans and animals. The only currently available vaccine against this disease is a live, attenuated vaccine, bacillus Calmette-Guérin (BCG), which was originally derived from Mycobacterium bovis and despite its variable efficacy is the most widely administered vaccine in the world. With the advent of the human immunodeficiency virus-AIDS pandemic concern has been raised over the safety of BCG. Moreover, since BCG sensitizes vaccinated individuals to the tuberculin test, vaccination with BCG prevents diagnosis of infection in vaccinated individuals. Recently, auxotrophic strains of BCG have been generated by insertional mutagenesis which have been shown to be safer than the parent BCG strain following administration to mice with severe combined immunodeficiency disease. These strains have also been shown to give comparable protection against intravenous and intratracheal challenge of BALB/c mice with M. tuberculosis relative to conventional BCG. Here we report that one of these mutants, a leucine auxotroph of BCG, conferred significant protection of the lungs and spleens of guinea pigs infected with M. bovis and protection of the spleens of guinea pigs infected with M. tuberculosis in the absence of a cutaneous hypersensitivity reaction to tuberculin. Therefore, protective immunity to tuberculosis may, at least in part, be achieved without sensitization to the tuberculin skin test. These results indicate that it may be possible to develop a new generation of vaccines based on BCG that are protective, are safe for use in the immunocompromised, and do not preclude the use of the tuberculin skin test in both humans and animals.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sabine Steinbach ◽  
Sasan Jalili-Firoozinezhad ◽  
Sreenidhi Srinivasan ◽  
Mariane B. Melo ◽  
Sonya Middleton ◽  
...  

AbstractBovine tuberculosis (bTB) is a disease of livestock with severe and worldwide economic, animal welfare and zoonotic consequences. Application of test-and-slaughter-based control polices reliant on tuberculin skin testing has been the mainstay of bTB control in cattle. However, little is known about the temporal development of the bovine tuberculin skin test response at the dermal sites of antigen injection. To fill this knowledge gap, we applied minimally-invasive sampling microneedles (SMNs) for intradermal sampling of interstitial fluid at the tuberculin skin test sites in Mycobacterium bovis BCG-vaccinated calves and determined the temporal dynamics of a panel of 15 cytokines and chemokines in situ and in the peripheral blood. The results reveal an orchestrated and coordinated cytokine and local chemokine response, identified IL-1RA as a potential soluble biomarker of a positive tuberculin skin response, and confirmed the utility of IFN-γ and IP-10 for bTB detection in blood-based assays. Together, the results highlight the utility of SMNs to identify novel biomarkers and provide mechanistic insights on the intradermal cytokine and chemokine responses associated with the tuberculin skin test in BCG-sensitized cattle.


2014 ◽  
Vol 21 (9) ◽  
pp. 1309-1313 ◽  
Author(s):  
Susan L. Baldwin ◽  
Valerie Reese ◽  
Brian Granger ◽  
Mark T. Orr ◽  
Gregory C. Ireton ◽  
...  

ABSTRACTThe tuberculin skin test (TST) is a simple and inexpensive test to determine whether individuals have been exposed toMycobacterium tuberculosis. This test is not always reliable, however, in people previously immunized with BCG and/or who have been exposed to environmental mycobacterial species due to a reaction to purified protein derivative (PPD) used in the skin test. An issue with BCG, therefore, is that the resulting sensitization to PPD in some individuals compromises the diagnostic use of the skin test. The ability to induce protective immune responses without sensitizing to the tuberculin skin test will be important properties of next-generation tuberculosis (TB) vaccine candidates. We show here that guinea pigs immunized with the candidate TB vaccine ID93/GLA-SE, currently in clinical trials, do not react to intradermal PPD administration. In contrast, positive DTH responses to both ID93 and components thereof were induced in ID93/GLA-SE-immunized animals, indicating robust but specific cellular responses were present in the immunized animals. Noninterference with the TST is an important factor for consideration in the development of a vaccine againstM. tuberculosis.


2006 ◽  
Vol 27 (5) ◽  
pp. 512-514 ◽  
Author(s):  
Elizabeth C. Frenzel ◽  
Georgia A. Thomas ◽  
Hend A. Hanna

At the time of hire, 4059 of 6522 healthcare workers required a 2-step tuberculin skin test; 114 workers (2.8%) demonstrated a boosted reaction after the second step. Boosted reactions were significantly associated with male sex and older age. A verbal history of previous tuberculin skin test results was not a reliable indicator of baseline tuberculin skin test status at the time of hire.


Sign in / Sign up

Export Citation Format

Share Document